NASDAQ:SCYX SCYNEXIS (SCYX) Stock Forecast, Price & News $2.59 +0.05 (+1.97%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$2.48▼$2.6150-Day Range$2.38▼$3.6752-Week Range$1.15▼$3.84Volume404,750 shsAverage Volume1.16 million shsMarket Capitalization$94.59 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media SCYNEXIS MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside305.4% Upside$10.50 Price TargetShort InterestHealthy4.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.51 to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector700th out of 986 stocksPharmaceutical Preparations Industry325th out of 473 stocks 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, SCYNEXIS has a forecasted upside of 305.4% from its current price of $2.59.Amount of Analyst CoverageSCYNEXIS has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.52% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SCYNEXIS has recently decreased by 7.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCYX. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for SCYX on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.36% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions49.92% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to decrease in the coming year, from $0.51 to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 25.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SCYNEXIS (NASDAQ:SCYX) StockSCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address SCYX Stock News HeadlinesMay 19, 2023 | seekingalpha.comScynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral RatingMay 19, 2023 | benzinga.comWBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant PathogensJune 8, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.May 16, 2023 | americanbankingnews.comQ3 2023 Earnings Estimate for SCYNEXIS, Inc. Issued By Brookline Capital Management (NASDAQ:SCYX)May 14, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for SCYNEXIS, Inc.'s Q2 2023 Earnings (NASDAQ:SCYX)May 12, 2023 | marketwatch.comSCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME(R) (Ibrexafungerp Tablets)May 12, 2023 | msn.comSCYNEXIS: Q1 Earnings InsightsMay 12, 2023 | finance.yahoo.comSCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)June 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 12, 2023 | finance.yahoo.comSCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)May 11, 2023 | finanznachrichten.deScynexis: SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | washingtonpost.comScynexis: Q1 Earnings SnapshotMay 8, 2023 | finance.yahoo.comSCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership, institutions own 48%April 27, 2023 | americanbankingnews.comSCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest UpdateApril 13, 2023 | finance.yahoo.comSCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in DenmarkApril 13, 2023 | 247wallst.comUnusual Call Option Trade in Scynexis Worth $37.65KApril 12, 2023 | msn.comUnusual Call Option Trade in SCYNEXIS (SCYX) Worth $37.65KApril 12, 2023 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to SellApril 11, 2023 | finance.yahoo.comWe Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) SoonApril 7, 2023 | americanbankingnews.comSCYNEXIS, Inc. (NASDAQ:SCYX) to Post Q1 2023 Earnings of ($0.28) Per Share, Brookline Capital Management ForecastsApril 6, 2023 | americanbankingnews.comGuggenheim Raises SCYNEXIS (NASDAQ:SCYX) Price Target to $9.00April 5, 2023 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Rating Reiterated by LADENBURG THALM/SH SHApril 5, 2023 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Stock Rating Upgraded by StockNews.comApril 3, 2023 | markets.businessinsider.comSCYNEXIS (SCYX) Receives a Buy from Ladenburg Thalmann & Co.March 31, 2023 | finance.yahoo.comScynexis (SCYX) Inks Antifungal Drug Deal With GSKMarch 31, 2023 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Price Target Raised to $10.00 at Maxim GroupMarch 22, 2023 | finance.yahoo.comSCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some lossesSee More Headlines SCYX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCYX Company Calendar Last Earnings3/31/2023Today6/08/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees36Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$15.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+303.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E Ratio5.10 P/E GrowthN/ANet Income$-62,810,000.00 Net Margins-1,648.61% Pretax Margin-1,648.61% Return on Equity-875.77% Return on Assets-77.67% Debt Debt-to-Equity Ratio14.04 Current Ratio1.31 Quick Ratio1.29 Sales & Book Value Annual Sales$5.09 million Price / Sales18.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book26.00Miscellaneous Outstanding Shares36,520,000Free Float34,925,000Market Cap$94.95 million OptionableOptionable Beta2.13 Key ExecutivesMr. David Gonzalez Angulo M.D. (Age 58)CEO, Pres & Director Comp: $631.69kMr. Scott Sukenick J.D. (Age 45)Chief Legal Officer & Corp. Sec. Comp: $542.05kMr. Ivor Macleod CPA (Age 62)M.B.A., Chief Financial Officer Debbie EtchisonExec. Director of CommunicationsMs. Daniella GiganteVP of HRKey CompetitorsTiziana Life SciencesNASDAQ:TLSARelmada TherapeuticsNASDAQ:RLMDvTv TherapeuticsNASDAQ:VTVTRVL PharmaceuticalsNASDAQ:RVLPApplied TherapeuticsNASDAQ:APLTView All CompetitorsInstitutional OwnershipState Street CorpBought 27,500 shares on 5/16/2023Ownership: 0.291%Susquehanna International Group LLPBought 36,900 shares on 5/16/2023Ownership: 0.000%Jane Street Group LLCBought 13,386 shares on 5/16/2023Ownership: 0.037%Cubist Systematic Strategies LLCBought 13,414 shares on 5/15/2023Ownership: 0.037%Belvedere Trading LLCBought 11,494 shares on 5/15/2023Ownership: 0.031%View All Institutional Transactions SCYX Stock - Frequently Asked Questions Should I buy or sell SCYNEXIS stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares. View SCYX analyst ratings or view top-rated stocks. What is SCYNEXIS's stock price forecast for 2023? 3 Wall Street research analysts have issued 1-year target prices for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $15.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 303.8% from the stock's current price. View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts. How have SCYX shares performed in 2023? SCYNEXIS's stock was trading at $1.56 at the start of the year. Since then, SCYX shares have increased by 66.7% and is now trading at $2.60. View the best growth stocks for 2023 here. When is SCYNEXIS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our SCYX earnings forecast. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) announced its quarterly earnings data on Friday, March, 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.21. The business had revenue of $1.52 million for the quarter, compared to analyst estimates of $1.28 million. SCYNEXIS had a negative net margin of 1,648.61% and a negative trailing twelve-month return on equity of 875.77%. When did SCYNEXIS's stock split? Shares of SCYNEXIS reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS). What is SCYNEXIS's stock symbol? SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX." Who are SCYNEXIS's major shareholders? SCYNEXIS's stock is owned by a number of institutional and retail investors. Top institutional investors include Kingdon Capital Management L.L.C. (4.10%), AIGH Capital Management LLC (3.17%), Stonepine Capital Management LLC (1.23%), BlackRock Inc. (1.04%), D.A. Davidson & CO. (0.91%) and AMH Equity Ltd (0.75%). Insiders that own company stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick. View institutional ownership trends. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SCYNEXIS's stock price today? One share of SCYX stock can currently be purchased for approximately $2.60. How much money does SCYNEXIS make? SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $94.95 million and generates $5.09 million in revenue each year. The company earns $-62,810,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. How can I contact SCYNEXIS? SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490. This page (NASDAQ:SCYX) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.